Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
BERKELEY HEIGHTS, N.J., May 10, 2017 -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017, at 4:20 p.m. PDT.
A live webcast of the presentation will be available on the “Events & Presentations” page in the “Investors” section of the Edge website. A replay of the presentation will be available for 90 days following the event.
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening neurological and other conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, which is bleeding around the brain due to a ruptured brain aneurysm. Edge is evaluating EG-1962 in two clinical studies: a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external ventricular drain, and a study of direct intracisternal administration of EG-1962. For additional information about Edge, please visit www.edgetherapeutics.com.
Forward-Looking Statements
This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions, including statements with respect to Edge’s future clinical plans, Edge’s ability to advance its portfolio of therapies toward commercialization and the potential effects of its products. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.
Investor Contact: Gregory Gin Edge Therapeutics, Inc. Tel: 1-800-208-EDGE (3343) Email: [email protected] Media Contact: Laura Bagby 6 Degrees Tel: 312-448-8098 Email: [email protected]
